Challenge of deep vein thrombolysis in a patient on rifampicin for pulmonary tuberculosis

Abstract

Administration of rifampin concomitantly with drugs that undergo biotransformation through cytochrome P-450 pathway can accelerate 
elimination of coadministered drugs. This short case report provides an evidence of rifampicin-warfarin interaction, both of which are 
metabolized through cytochrome P-450 enzymes in the liver. This finding is significant to emphasize upon the need for vigilant monitoring to achieve the desired anticoagulation effect of warfarin in a patient already on long-term rifampicin, and the dose of warfarin may have to be greatly increased to achieve the desired therapeutic effect.